Department of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
BJOG. 2018 Nov;125(12):1550-1556. doi: 10.1111/1471-0528.15293. Epub 2018 Jun 25.
To evaluate the risk for major malformations following first-trimester exposure to vaginal azoles.
A population-based retrospective cohort study of women exposed to vaginal azoles from the first day of the last menstrual period until the 90th gestational day.
A combination of four computerised databases: medications, birth, infant hospitalizations, and pregnancy terminations.
All women who gave birth or underwent a pregnancy termination at Soroka Medical Center, Beer-Sheva, Israel, between 1999 and 2009.
Crude and adjusted relative risks for major congenital malformations and for specific malformations according to organ systems were calculated using a multivariate negative binomial regression. Potential confounders were assessed and controlled for included parity, maternal age, ethnicity, maternal diabetes, smoking, and year of birth or pregnancy termination. Additional analysis using propensity score matching was performed for selected malformations.
Major malformations as well as specific malformations according to organ systems.
Of 101 615 pregnancies, 1993 (1.96%) were exposed to clotrimazole vaginal tablets and 313 (0.31%) to miconazole vaginal tablets during the first trimester of pregnancy. No association was found between first-trimester exposure to clotrimazole and major or specific malformations. An association was found between miconazole exposure and musculoskeletal malformation in general and other congenital musculoskeletal anomalies in particular. However, no association was detected when propensity score matching was used.
Intrauterine exposure to vaginal azoles during the first trimester of pregnancy was not associated with either major or specific malformations according to organ systems.
First-trimester exposure to vaginal azoles is not associated with either major or specific malformations.
评估女性在妊娠早期接触阴道唑类药物后发生重大畸形的风险。
一项基于人群的回顾性队列研究,纳入了自末次月经第一天至妊娠第 90 天期间接触阴道唑类药物的女性。
四个计算机数据库的组合:药物、分娩、婴儿住院和妊娠终止。
1999 年至 2009 年期间在以色列贝尔谢巴索拉卡医疗中心分娩或行妊娠终止的所有女性。
使用多变量负二项回归计算重大先天畸形和特定器官系统畸形的粗相对风险和调整相对风险。评估并控制了潜在混杂因素,包括产次、母亲年龄、种族、母亲糖尿病、吸烟和出生年份或妊娠终止年份。对于选定的畸形,还进行了倾向评分匹配的额外分析。
重大畸形以及特定器官系统畸形。
在 101615 例妊娠中,有 1993 例(1.96%)在妊娠早期接触克霉唑阴道片,313 例(0.31%)接触咪康唑阴道片。妊娠早期接触克霉唑与重大或特定畸形之间无关联。米康唑暴露与骨骼肌肉畸形以及其他先天性骨骼肌肉异常有关。然而,当使用倾向评分匹配时,未发现关联。
妊娠早期阴道唑类药物暴露与重大或特定器官系统畸形无关。